Cryoport, Inc. (CYRX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Cryoport, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences, focusing on regenerative medicine. The reporting period is significantly impacted by the completion of the divestiture of its specialty courier business, CRYOPDP, to DHL on June 11, 2025. Consequently, CRYOPDP results are classified as discontinued operations.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue (Continuing Ops) | $44.2 million | $38.3 million | $130.7 million | $115.3 million |
| Gross Margin | $21.3 million (48.2%) | $17.4 million (45.5%) | $61.3 million (46.9%) | $50.2 million (43.5%) |
| Net Income (Loss) | $(6.9) million | $0.8 million | $89.9 million | $(96.1) million |
| Net Income (Loss) Attributable to Common | $(8.9) million | $(1.2) million | $83.9 million | $(102.1) million |
| Cash and Cash Equivalents | $255.8 million (as of Sept 30, 2025) | |||
| Short-Term Investments | $165.5 million (as of Sept 30, 2025) | |||
| Convertible Senior Notes (Long-Term) | $184.8 million (as of Sept 30, 2025) | |||
| Working Capital | $454.1 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Continuing operations revenue increased 15.4% in Q3 and 13.4% YTD compared to the prior year, driven by growth in BioLogistics Solutions (+14.6% Q3) and BioStorage/BioServices (+21.5% Q3).
- Discontinued Operations Impact: The YTD 2025 net income of $89.9 million is primarily driven by a $120.0 million gain on the sale of the CRYOPDP business recorded in discontinued operations. Without this gain, the company reported a loss from continuing operations of $25.4 million YTD.
- Debt Reduction: The company repaid the $14.3 million 2025 Senior Notes at maturity in June 2025. No repurchases of the 2026 Senior Notes occurred in Q3 2025, unlike the significant repurchases in Q3 2024 which generated a $17.3 million gain on extinguishment of debt.
- Impairment: There were no impairment losses in Q3 2025, compared to a $63.8 million impairment loss recorded in the prior year period related to the MVE reporting unit.
- Stock Repurchases: The company repurchased 483,397 shares of common stock in Q3 2025 for $3.7 million and 1.1 million shares YTD for $8.0 million.
Guidance, Outlook, and Risks
- Strategic Partnership: Management expects the divestiture and strategic partnership with DHL to enhance business development in EMEA and APAC regions.
- Liquidity: Management believes current cash, cash equivalents, and short-term investments ($421.3 million total) are sufficient to meet operational requirements for at least the next 12 months.
- Repurchase Programs: Approximately $65.9 million of repurchase authorization remains available under the 2022 and 2024 programs.
- Risks:
- Government Shutdown: A continued U.S. federal government shutdown could delay customer purchases and funding, materially affecting results.
- Foreign Exchange: Revenue from international business (approx. 18% of consolidated revenue) is exposed to currency fluctuations (Euros, British Pounds, Chinese Yuan).
- Interest Rates: Fluctuations in interest rates affect the fair value of the company's fixed-rate debt and investment portfolio.
Investor Verification Checklist
- Verify the sustainability of revenue growth in continuing operations excluding the one-time gain from the CRYOPDP divestiture.
- Confirm the timeline and financial impact of the strategic partnership with DHL in EMEA and APAC regions.
- Monitor the company's ability to maintain positive Adjusted EBITDA from continuing operations, which was negative $0.6 million in Q3 2025.
- Review the maturity schedule and interest obligations of the remaining $186.2 million in 2026 Convertible Senior Notes.
- Assess the impact of the U.S. federal government shutdown on customer demand and cash flow.